When the heart is injured or strained, molecules called Cardiac Biomarkers are released into the bloodstream.
![]() |
| Cardiac Biomarkers |
Cardiac Biomarkers are
used to diagnose and risk stratify patients with chest discomfort and suspected
acute coronary syndrome (ACS), as well as to treat and predict outcomes in
patients with acute heart failure, pulmonary embolism, and other diseases.
A cardiac biomarker is a protein-based molecule that may be
measured for heart disease prognosis and diagnosis. When the heart is injured
or stressed, such as from a lack of oxygen, cardiac biomarkers are released
into the bloodstream. Cardiovascular biomarkers including cardiac troponin,
creatinine kinase, myoglobin, and others are used to diagnose disorders like
ACS and heart ischemia.
According to Coherent
Market Insights, The global Cardiac
Biomarker Market is estimated to be valued at US$ 8,099.9 Mn in 2021
and is expected to exhibit a CAGR of 10.2% during the forecast period
(2021-2028).
Cardiac biomarkers are protein molecules released into the
bloodstream as a result of cardiac injury or stress. These biomarkers might be
used to diagnose a variety of cardiovascular disorders, such as cardiac
ischemia, myocardial infarction, congestive heart failure, and acute coronary
syndrome (ACS). Cardiac biomarker testing enable doctors to assess a patient's
likelihood of developing such conditions.
These tests are done if a patient has chest discomfort.
Troponin, creatine kinase-muscle/brain (CK-MB), B-type natriuretic peptide
(BNP), high-sensitivity C-reactive protein (hs-CRP), and other cardiac
biomarkers are commonly evaluated for CVD. Myocardial muscle creatine kinase
(CK-MB), troponin I and T, myoglobin, brain natriuretic peptides (BNPs),
ischemia modified albumin (IMA), and other cardiac biomarkers are commonly employed
as an integrated diagnostic method for cardiovascular diseases (CVDs).
The impact of the COVID-19 pandemic on the cardiac
biomarkers testing sector is predicted to be good. As a result of a rise in the
number of COVID-19 patients who have pre-existing medical conditions such as
cardiovascular disease and others. COVID-19 people with pre-existing medical
disorders, such as cardiovascular disease, are more likely to have a heart
attack. Troponin levels were also found to be considerably greater in COVID-19
patients who died or were seriously sick. This has resulted in an upsurge in
the need for cardiac biomarker testing among COVID-19 patients. Considering all
of these variables, global cardiac
biomarkers have grown in popularity throughout the pandemic and
are predicted to continue to expand in the coming years.
In the next years, the market is likely to be driven by an
increase in the senior population and an increase in the number of patients
suffering from heart attacks and chest discomfort as a result of changing
lifestyles. Furthermore, an increase in public and private financing for
cardiac biomarker research is likely to promote growth in the future years.
However, problems such as low specificity in certain situations and adverse
effects associated with cardiac biomarkers, such as skeletal muscle damage, are
expected to stymie the market's expansion in the future years.
Read the Research
report- https://bit.ly/3Nd04sk

Comments
Post a Comment